Inventor · disambiguated record
Weijun Feng
Also filed as: FENG WEIJUN
9 granted patents·11 pending applications·30 citations·filing 1999–2024
85Inventor score
Files withAPPLIED MOLECULAR TRANSPORT INC12THORNHILL THERAPEUTICS INC4SHANGHAI HENLIUS BIOTECH INC2UNIV CALIFORNIA2
Top patents by PatentIndex Score
20 records- 0196US11027020B2Delivery constructs for transcytosis and related methodsAPPLIED MOLECULAR TRANSPORT INC·Filed 2020·Granted Jun 8, 2021·7 cites·15 claims
- 0293US11160869B2Compositions, formulations and interleukin production and purificationAPPLIED MOLECULAR TRANSPORT INC·Filed 2021·Granted Nov 2, 2021·4 cites·25 claims
- 0392US11214606B2Compositions, formulations and interleukin production and purificationAPPLIED MOLECULAR TRANSPORT INC·Filed 2021·Granted Jan 4, 2022·3 cites·18 claims
- 0491US11324833B2Cholix-derived carriers for oral delivery of heterologous payloadAPPLIED MOLECULAR TRANSPORT INC·Filed 2020·Granted May 10, 2022·2 cites·16 claims
- 0590US11479593B2Compositions, formulations and interleukin production and purificationAPPLIED MOLECULAR TRANSPORT INC·Filed 2021·Granted Oct 25, 2022·1 cites·30 claims
- 0682US2025108118A1Cholix-derived carriers for oral delivery of heterologous payloadTHORNHILL THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 0778US11466067B2Compositions, formulations and interleukin production and purificationAPPLIED MOLECULAR TRANSPORT INC·Filed 2021·Granted Oct 11, 2022·0 cites·17 claims
- 0878US2024238429A1Delivery constructs for transcytosis and related methodsTHORNHILL THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 0977US2024009316A1Cholix-derived carriers for oral delivery of heterologous payloadAPPLIED MOLECULAR TRANSPORT INC·Filed 2022·Application pending·0 cites
- 1073US2025242039A1Toxin-derived delivery constructsTHORNHILL THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1172US11504433B2Cholix-derived carriers for oral delivery of heterologous payloadAPPLIED MOLECULAR TRANSPORT INC·Filed 2020·Granted Nov 22, 2022·0 cites·20 claims
- 1271US2024299565A1Toxin-derived delivery constructsTHORNHILL THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 1369US2023158163A1Toxin-derived delivery constructsAPPLIED MOLECULAR TRANSPORT INC·Filed 2022·Application pending·0 cites
- 1468US2021338828A1Delivery constructs for transcytosis and related methodsAPPLIED MOLECULAR TRANSPORT INC·Filed 2021·Application pending·0 cites
- 1565US11426466B2Toxin-derived delivery constructs for pulmonary deliveryAPPLIED MOLECULAR TRANSPORT INC·Filed 2020·Granted Aug 30, 2022·0 cites·29 claims
- 1659US2023067770A1Anti-cd137 constructs, multispecific antibody and uses thereofSHANGHAI HENLIUS BIOTECH INC·Filed 2022·Application pending·0 cites
- 1759US2022403040A1Anti-cd137 constructs, multispecific antibody and uses thereofSHANGHAI HENLIUS BIOTECH INC·Filed 2022·Application pending·0 cites
- 1848US6965850B2Methods for modulating nuclear receptor coactivator bindingUNIV CALIFORNIA·Filed 1999·Granted Nov 15, 2005·13 cites·40 claims
- 1947US2020140511A1Delivery constructs for transcytosis and related methodsAPPLIED MOLECULAR TRANSPORT INC·Filed 2019·Application pending·0 cites
- 2046US2006149521A1Modulating nuclear receptor coactivator bindingUNIV CALIFORNIA·Filed 2005·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Weijun Feng files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →